Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online March 13, 2009
The Oncologist, Vol. 14, No. 3, 276-283, March 2009; doi:10.1634/theoncologist.2009-0003
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0003v1
14/3/276    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Related articles in The Oncologist
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sezer, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sezer, O.

Myelomas

Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment

Orhan Sezer

Department of Hematology and Oncology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Key Words. Multiple myeloma • Bone • Biochemical markers • Osteoclast • Osteoblast • RANKL • Osteoprotegerin • MIP-1 • DKK-1 • ICTP

Correspondence: Orhan Sezer, M.D., Ph.D., Department of Hematology and Oncology, Charité – Universitätsmedizin Berlin, 10117 Berlin, Germany. Telephone: 49-30-450-613105; Fax: 49-30-450-527907; e-mail: sezer{at}charite.de

Received January 7, 2009; accepted for publication February 16, 2009; first published online in THE ONCOLOGIST Express on March 13, 2009.

Disclosures: Orhan Sezer: Honoraria: Amgen, Novartis, Ortho-Biotech; Research funding/contracted research: Janssen-Cilag, Novartis.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Bone disease is a hallmark of multiple myeloma (MM). Occurring in the majority of MM patients, it is associated with bone pain, fractures, and hypercalcemia and has major impacts on quality of life. Furthermore, bone resorption activity has been shown to be an independent risk factor for overall survival in patients with symptomatic MM. Myeloma is characterized by a unique form of bone disease with lytic bone destruction that is not followed by reactive bone formation (uncoupling). This review focuses on recent advances in our understanding of the biology of osteoclast activation and osteoblast inhibition in MM, diagnostic standards, and recent progress in treatment options for myeloma bone disease. Translational research has enabled a rapid transfer of mechanistic insights from the bench to the bedside and will hopefully result in better treatment options and outcome for patients in near future.


Related articles in The Oncologist:

Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?
Franco Silvestris, Sabino Ciavarella, Monica De Matteo, Marco Tucci, and Franco Dammacco
The Oncologist 2009 14: 264-275. [Abstract] [Full Text]  





HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.
Advertisement